Kiniksa Pharmaceuticals Ltd expected to post a loss of 79 cents a share - Earnings Preview

Kiniksa Pharmaceuticals International

30/07/2021 18:05

* Kiniksa Pharmaceuticals Ltd  KNSA.OQ   KNSA.O  is expected
to show a rise in quarterly revenue when it reports results on
August 3. 
* The Hamilton, Bermuda-based company is expected to report
revenue of $3.969 million, according to the mean estimate from 4
analysts, based on Refinitiv data.  
​* Refinitiv's mean analyst estimate for Kiniksa Pharmaceuticals
Ltd is for a loss of 79 cents per share. For the same quarter
last year, the company reported a loss of 65 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Kiniksa
Pharmaceuticals Ltd is $33​, about 54.8% above​ its last closing
price of $14.93. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.63       -0.72      -0.72     Met     0.7
 Dec. 31 2020  -0.61       -0.62      -0.79     Missed  -26.9
 Sep. 30 2020  -0.60       -0.60      -0.66     Missed  -9.1​
 Jun. 30 2020  -0.60       -0.63      -0.65     Missed  -3.8
 Mar.          -0.67​      -0.63      -0.48     Beat    24.3​
 31​ 2020​                                              
 Dec. 31 2019  -0.64       -0.62      -0.58     Beat    6.5​
 Sep. 30 2019  -0.74       -0.72      -0.49     Beat    31.7
 Jun. 30 2019  -0.71       -0.72      -0.68     Beat    5.2
 This summary was machine generated July 30 at 17:05 GMT.  All
figures in US dollars unless otherwise stated